High-risk localized prostate cancer
This study will look at how well the PARP Inhibitor niraparib works, when given before a radical prostatectomy, for people with high-risk prostate cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1.
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHK1, CHK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only.
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.
Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene
The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L.
Treatment in people with aggressive metastatic prostate cancer
This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (niraparib), and an immunotherapy agents (cetrelimab) works for treating people with a rare type of prostate cancer known as aggressive variant prostate cancer (AVPC). The research will compare the benefits of giving niraparib with or without cetrelimab, after treatment with chemotherapy.
Newly diagnosed prostate cancer grade group 3-5
This study will look at treating men with high risk prostate cancer using the PARP inhibitor, niraparib combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone. Phase 1 of this study will look at the best dose of niraparib for this treatment combination. The phase 2 portion of this study will look at the 3-year PSA recurrence free-survival rate of the patients who received this combined therapy.
Advanced ovarian, breast, prostate or pancreatic cancer
PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.
Advanced solid tumors
This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage.
Advanced solid tumors
This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.
Additional Results on Clinicaltrials.gov Treatment + Prostate Cancer + PARP
Pembro With Radiation With or Without Olaparib
NCT ID: NCT05568550 (https://classic.clinicaltrials.gov/show/NCT05568550)
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
NCT ID: NCT04194554 (https://classic.clinicaltrials.gov/show/NCT04194554)
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT ID: NCT04030559 (https://classic.clinicaltrials.gov/show/NCT04030559)
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
NCT ID: NCT05807126 (https://classic.clinicaltrials.gov/show/NCT05807126)
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
NCT ID: NCT04336943 (https://classic.clinicaltrials.gov/show/NCT04336943)
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
NCT ID: NCT04592237 (https://classic.clinicaltrials.gov/show/NCT04592237)
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
NCT ID: NCT03317392 (https://classic.clinicaltrials.gov/show/NCT03317392)
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
NCT ID: NCT05498272 (https://classic.clinicaltrials.gov/show/NCT05498272)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://classic.clinicaltrials.gov/show/NCT04644068)
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
NCT ID: NCT05501548 (https://classic.clinicaltrials.gov/show/NCT05501548)
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT ID: NCT04703920 (https://classic.clinicaltrials.gov/show/NCT04703920)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://classic.clinicaltrials.gov/show/NCT04550494)
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT ID: NCT04734730 (https://classic.clinicaltrials.gov/show/NCT04734730)
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
NCT ID: NCT03047135 (https://classic.clinicaltrials.gov/show/NCT03047135)
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
NCT ID: NCT04267939 (https://classic.clinicaltrials.gov/show/NCT04267939)
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT05005728 (https://classic.clinicaltrials.gov/show/NCT05005728)
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
NCT ID: NCT04951492 (https://classic.clinicaltrials.gov/show/NCT04951492)
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT ID: NCT05700669 (https://classic.clinicaltrials.gov/show/NCT05700669)
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
NCT ID: NCT02769962 (https://classic.clinicaltrials.gov/show/NCT02769962)
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
NCT ID: NCT04586335 (https://classic.clinicaltrials.gov/show/NCT04586335)
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://classic.clinicaltrials.gov/show/NCT05489211)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT ID: NCT03682289 (https://classic.clinicaltrials.gov/show/NCT03682289)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05252390 (https://classic.clinicaltrials.gov/show/NCT05252390)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://classic.clinicaltrials.gov/show/NCT05417594)
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.